State Street’s Ovid Therapeutics OVID Stock Holding History

State Street’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.16M	Buy	520,283 +243,750	+88%	+$436K	﹤0.01%	3458
2025 Q4	$451K	Buy	276,533 +49,500	+22%	+$76.2K	﹤0.01%	3707
2025 Q3	$295K	Hold	227,033	–	–	﹤0.01%	3796
2025 Q2	$74.9K	Sell	227,033 -1,145,075	-83%	-$345K	﹤0.01%	4026
2025 Q1	$428K	Sell	1,372,108 -22,410	-2%	-$13.8K	﹤0.01%	3628
2024 Q4	$1.3M	Buy	1,394,518 +33,063	+2%	+$37K	﹤0.01%	3429
2024 Q3	$1.61M	Buy	1,361,455 +7,084	+0.5%	+$7.4K	﹤0.01%	3390
2024 Q2	$1.04M	Buy	1,354,371 +198,724	+17%	+$553K	﹤0.01%	3468
2024 Q1	$3.52M	Buy	1,155,647 +35,300	+3%	+$118K	﹤0.01%	3068
2023 Q4	$3.61M	Buy	1,120,347 +11,288	+1%	+$38.6K	﹤0.01%	3099
2023 Q3	$4.26M	Buy	1,109,059 +82,428	+8%	+$296K	﹤0.01%	2993
2023 Q2	$3.37M	Buy	1,026,631 +834,898	+435%	+$2.83M	﹤0.01%	3185
2023 Q1	$495K	Hold	191,733	–	–	﹤0.01%	3748
2022 Q4	$357K	Hold	191,733	–	–	﹤0.01%	3885
2022 Q3	$353K	Hold	191,733	–	–	﹤0.01%	3906
2022 Q2	$412K	Hold	191,733	–	–	﹤0.01%	3907
2022 Q1	$602K	Buy	191,733 +46,884	+32%	+$147K	﹤0.01%	3970
2021 Q4	$465K	Hold	144,849	–	–	﹤0.01%	4053
2021 Q3	$487K	Sell	144,849 -12,000	-8%	-$43.8K	﹤0.01%	3989
2021 Q2	$613K	Sell	156,849 -1,047,516	-87%	-$4.13M	﹤0.01%	3790
2021 Q1	$4.84M	Buy	1,204,365 +464,925	+63%	+$1.54M	﹤0.01%	3069
2020 Q4	$1.71M	Buy	739,440 +12,208	+2%	+$56.9K	﹤0.01%	3419
2020 Q3	$4.17M	Sell	727,232 -8,724	-1%	-$58.4K	﹤0.01%	2870
2020 Q2	$5.42M	Buy	+735,956	New	+$3.44M	﹤0.01%	2722
2019 Q2	–	Sell	-187,915	Closed	-$333K	–	3839
2019 Q1	$333K	Buy	187,915 +18,100	+11%	+$45.3K	﹤0.01%	3510
2018 Q4	$411K	Sell	169,815 -13,949	-8%	-$63.7K	﹤0.01%	3473
2018 Q3	$1.04M	Buy	183,764 +43,020	+31%	+$326K	﹤0.01%	3403
2018 Q2	$1.1M	Buy	140,744 +35,016	+33%	+$301K	﹤0.01%	3389
2018 Q1	$747K	Buy	105,728 +30,162	+40%	+$244K	﹤0.01%	3381
2017 Q4	$748K	Buy	75,566 +3,631	+5%	+$33.3K	﹤0.01%	3396
2017 Q3	$616K	Buy	71,935 +22,335	+45%	+$186K	﹤0.01%	3447
2017 Q2	$520K	Buy	+49,600	New	+$648K	﹤0.01%	3413

Other funds holding OVID

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Street's OVID Position: Q1 2026 in Review

State Street increased its Ovid Therapeutics (OVID) stake by 88% in Q1 2026, buying an estimated $436K and bringing the position to 520,283 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

State Street first reported a position in OVID in Q2 2017 and has held it in 32 quarters since. The position peaked at $5.42M in Q2 2020. 103 funds tracked by Wall St. Rank hold OVID as of Q1 2026.

State Street held 520,283 shares of Ovid Therapeutics worth $1.16M as of Q1 2026.
State Street bought 243,750 Ovid Therapeutics shares in Q1 2026, an estimated $436K.
Ovid Therapeutics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3458 holding.
State Street first reported a position in Ovid Therapeutics in Q2 2017 and has held it in 32 quarters since.
State Street's Ovid Therapeutics position peaked at $5.42M in Q2 2020.
103 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.